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Calcium oxalate dihytirate formation in urine. Factors that promote
the formation of calcium oxalate dihydrate (COD) in urine were
investigated. Crystals resulting from the incubation of 25-mi aliquots of
the solution to be tested and I ml of 0.05 M ammonium oxalate were
examined by infrared spectrophotometry. With reference spectra of
known mixtures, the fractional content of COD could be estimated. At
pH 6.5, only COD formed in human urine. In a supersaturated inorganic
solution of calcium oxalate, the percentage of COD was 7.5 1.4.
Pyrophosphate (I to 8 x 10 M), citrate (l0 to 2 )< l0- M), RNA
fromyeast(5xl09100.SxlO7M),orheparin(2xl09to2xl0
M) added to a supersaturated solution of calcium oxalate increased the
percentage of COD proportional to the concentration of the additives.
Chondroitin sulfate and magnesium had no effect. An increase in pH
increased the formation of COD in inorganic solutions containing
citrate, pyrophosphate, and heparin and in undiluted urine. RNA-
citrates and citrate-pyrophosphate mixtures showed additivity. Urine
showed an effect that was inversely proportional to its dilution.
Substances that promote COD formation in this system had their phase-
stabilizing effects at concentrations normally found in urine. Further,
these same substances are known inhibitors of calcium oxalate crystal
formation. With both inhibition and phase stabilization, there is additiv-
ity of effects, and changes in pH alter the response.
Formation de l'oxalate de calcium dihydraté clans les urines. Les
facteurs facilitant Ia formation de l'oxalate de calcium dihydraté (COD)
dans les urines ont été explores. Les cristaux resultant de l'incubation
d'aliquotes de 25 ml de Ia solution a tester et de I ml d'oxalate
d'ammonium a 0,05 M ont ete examines par spectrophotometrie infra-
rouge. Avec les spectres de référence de mélanges connus, le contenu
fractionnel en COD pouvait étre estimé. A pH 6,5, seul du COD se
formait dans les urines humaines. Dans une solution inorganique
sursaturée d'oxalate de calcium, le pourcentage de COD était de 7,5
1,4. Du pyrophosphate (I a 8 x 10 si). du citrate (l0- a 0,5 x l0- M)
ou de l'héparine (2 x lO a 2 x l0 M) ajoutés a une solution
sursaturëe d'oxalate de calcium augmentaient le pourcentage de COD
proportionneliment a Ia concentration des substances ajoutees. Le
sulfate de chondroltine et Ic magnesium étaient sans effet. Une éléva-
tion de pH augmentait Ia formation de COD dans des solutions
inorganiques contenant du citrate, du pyrophosphate ou de l'héparine et
dans des urines non diluées. Les mélanges RNA-citrates et citrates-
pyrophosphates présentaient une additivité. Les specimens urines
presentaient un effet inversement proportionnei a leur dilution. Les
substances qui facilitent Ia formation de COD dans le système avaient
leurs effets stabilisants de phase aux concentrations normalement
trouvées dans les urines. En outre, ces mémes substances sont des
inhibiteurs connus de Ia formation de cristaux d'oxalate de calcium.
Avec l'inhibition et Ia stabilisation de phase, ii existe une additivité des
effets, et les modifications de pH altèrent Ia réponse.
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Calcium oxalate is the most common crystalline constituent
of urinary stones. In urine, calcium oxalate occurs as two
different phases: calcium oxalate monohydrate (COM) and
calcium oxalate dihydrate (COD). COM is the predominant
constituent of kidney stones [I, 2]. For this reason, COM has
been studied extensively. However, COD is the most common
secondary deposit in kidney stones [3]. Moreover, COD is the
most frequent calcium oxalate crystal present in the urine of
patients with idiopathic calcium urolithiasis [4].
Data showing that COD is less stable and possibly a transi-
tional form for COM suggest that COD may have a more
important role than previously believed [5]. COM is easily
obtainable in vitro from simple supersaturated solutions of
calcium oxalate, but COD is much more difficult to precipitate
from synthetic solutions, and the methods are not consistently
reproducible [6, 7]. Magnesium or trace metals may stabilize
the COD [8, 9]. The observation that COD crystals may be
obtained almost exclusively from precipitation of a mixture of
ammonium oxalate and human whole urine [101 suggests that
urine contains specific substances that favor the formation of
COD over COM.
We investigated the effect of additives, including some inhibi-
tors of calcium oxalate crystal growth, on the formation of COD
and on the relative proportion of COD to COM that is formed.
The influence of pH on the effect of inhibitors also was studied.
Mixtures of inhibitors in simple synthetic solutions and com-
plex mixtures (human urine) were investigated for their abilities
to form COD in this system.
Methods
Reagent-grade chemicals were used without further purifica-
tion. The synthetic solutions used in all the experiments were
crystal-free solutions of calcium chloride and sodium oxalate in
0.1 M sodium chloride. Concentrations of calcium, oxalate, and
sodium were, respectively, 8.3 mtvi, 1.3 m, and 0.1 M. These
concentrations of calcium and oxalate led to a calcium oxalate
supersaturation of 3.4, as computed with an ion-equilibrium
computer program [11]. This supersaturation was identical to
that of a chemically characterized urine poo1 collected from
normal adult males. By the use of 0.1 Mhydrochloric acid or 0.1
M sodium hydroxide, the solutions were adjusted to a pH of 6.5,
which was identical to the pH of the urine pool. Experiments
were performed at room temperature (22°C). For each experi-
ment a 25-mi portion was added rapidly to I ml of 0.05 M
ammonium oxalate in an 18 x 150 mm test tube (Pyrex). Mixing
was done by inverting the tube five times during 30 sec. Each
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mixture was then allowed to incubate without stirring for 7 mm,
after which it was vacuum-filtered through a 0.2-sm filter
(Nuclepore Corp., Pleasanton, California). Crystals were col-
lected from the filter by scratching the surface with a scalpel
blade. One milligram of the collected crystals was used for
infrared spectrophotometric analysis to determine the fractional
content in the percentage of COD.
Quantitative estimation of the percentage of dihydrate in the
samples. One milligram of the crystals collected on each filter
was mixed with 200 mg of infrared-grade potassium bromide
and ground in an agate mortar to obtain a suitable fine powder.
The powder was transferred to a die and pressed at 8 tons/cm2
for 10 mm. The resulting pellet was run in an infrared spectro-
photometer (Beckman IR 18, Beckman Instruments, Inc., Ful-
lerton, California). Differentiation of COM and COD is done by
analysis of the recorded spectrum [12]. Certain wavelengths are
characteristic of each of these hydrates [13]. COM presents a
highly characteristic sharp peak of transmission at 780 cm
and a medium broad peak at 640 cm, whereas COD presents a
characteristic sharp peak at 910 cm and a medium broad peak
at 780 cm. The other characteristic peaks of COM below 600
cm were not used. A quantitative estimation of the fractional
content of COD can be made by the analysis of the ratio of the
absorbance of the sample at two characteristic wavelengths
[121. Mixtures of COM (reagent grade) and COD obtained from
a pure COD stone were used as standards. The ratio (R) of the
log of the transmission at 910 and 780 cm' was plotted against
the fractional content in the percentage of COD present in the
mixture, and a linear reference curve was obtained (Fig. 1) (r =
0.98, P < 0.005). The resulting regression equation
y = 302.IR — 11.9 (1)
was used to calculate y, the fractional content in percentage of
COD in the sample. The use of a ratio of the log transmission at
910 cm to the log transmission at 640 cm led to similar
results (r = 0.96). The confidence interval for the percentage of
dihydrate obtained by these calculations was less than 5% for
extreme values.
Effect of additives on the synthetic solution of calcium
oxalate. Several substances were tested at various concentra-
tions at pH 6.5. These included sodium pyrophosphate (Ito 8 x
10-s M), sodium citrate (10 to 2 x l0 M), magnesium
chloride (l0 to 10—2 M), chondroitin sulfate (grade 3, Sigma
Chemical Company, St. Louis, Missouri) (106 to 1.6 x l0
M), heparin (grade 1, Sigma Chemical Company) (2 x i09 M to
2 x l0 M), and RNA (from yeast, type 11, Sigma Chemical
Company) (5 x iO to 5 x i0 NO. The molecular weights for
heparin, chondroitin sulfate, and RNA of 20,000, 50,000, and
120,000, respectively, were used.
In the experiments with citrate and magnesium, the ability of
these compounds to form complexes with calcium reduces the
calcium oxalate supersaturation. The concentrations of calcium
and oxalate, therefore, were adjusted by using the ion-equilibri-
um computer program [11110 maintain constant the supersatu-
ration for calcium oxalate.
The result of each experiment (for example, the percentage of
dihydrate obtained) was plotted against the corresponding
concentration for each inhibitor. For each concentration of
inhibitor, three to six different assays were performed.
The effect of pH on inhibitor solutions was tested for pyro-
phosphate (5 X io M), citrate (1.25 x l0 M), and RNA (1.6
x l0 M and 4.2 x l0 M) from pH 4.5 to 7.5.
Effect of inhibitor mixtures. The effect of the additivity of
inhibitors was tested for the combinations of RNA-pyrophos-
phate and citrate-pyrophosphate at pH 6.5. The concentrations
of the inhibitors in the mixtures were calculated from Eqs. (2),
(3), and (4) (see Results), obtained for each inhibitor separately
at pH 6.5, to give approximately 35 and 15% COD for the RNA-
pyrophosphate mixture experiments, respectively, and 25 and
25% COD for the citrate-pyrophosphate experiments. The
results obtained in eight assays for each inhibitor mixture were
compared with the sum of the effect of each inhibitor tested
separately at the same concentration and pH and with the sum
of the effect of each inhibitor, calculated from Eqs. (2), (3), and
(4).
Effect of human urine. Urine from the pool (see above) was
stored frozen in 200-mI bottles. After thawing, the urine was
vacuum-filtered through a 0.2 M filter (Nuclepore) to remove
crystals and particles. The effect of the addition of this urine to
the synthetic medium was tested at different dilutions at pH 6.5.
Mixtures containing (vol/vol) 0%, 25%, 50%, 75%, and 100%
urine were tested. The influence of pH variation on undiluted
urine from this pool was studied between pH 4.5 and 7.
Analysis of data. The data obtained with each inhibitor and
with the variation in pH were examined by linear regression
analysis. If there was a strong linear relationship (r > 0.90), an
equation was developed and used in further calculations.
Results
Effect of additives. A strong linear relationship was found
between the percentage of COD and the concentration of
pyrophosphate(r = 0.98;P <0.01), citrate (r = 0.92; P <0.01),
RNA (r = 0.94; P < 0.01), and heparin (r 0.96; P < 0,01). This
relationship with the concentration of inhibitor was linear until
the inhibitor concentrations reached a value above which a
plateau was observed (Fig. 2). The level of the plateau was
different for each inhibitor. Pyrophosphate at a concentration of
6 x l0 NI and above produced 68% COD; citrate at a
concentration of 1.5 x l0 M and above, 54.6% COD; heparin
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Fig. 1. Relationship between the percentage of calcium oxalate dihy-
drate crystals in a ,nixture with calcium oxalate monohvdrate and the
ratio of the log transmission 019/0cm' and 780 cm (r = 0.98. P <
0.005).
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at a concentration of 1.65 x 10 M and above, 49%; and RNA
at 5 x l0 M and above, 33%. The following regression
equations were used to calculate the concentrations of inhibitor
in the inhibitor-mixture experiments:
For RNA: y = O.49x + 6.6
For pyrophosphate: y = 990,000x + 8.8
For citrate: y = 30,300x + 9.3
in which y represents the percentage of COD and x the
concentration of the substance considered in moles per liter;
RNA is expressed in milligrams per liter.
Pyrophosphate and citrate showed their effects at concentra-
tions corresponding to concentrations found in normal urine.
Similarly, RNA had an effect in the concentration range of
i07 M, aconcentration identical to the estimated concentration
of RNA-like material in urine [14]. Chondroitin sulfate and
magnesium at the concentrations used did not increase the
percentage of COD in this system.
Effect of pH variations. For pyrophosphate and citrate, a
linear relationship was observed for the pH variation with the
COD percentage (respectively, r = 0.97, P < 0.01 and r = 0.86,
P <0.01), whereas RNA values showed a different pattern (Fig.
3). ForRNA, a U-shaped curve was obtained; the lowest values
of COD were observed for pH 5.5. Urine samples showed a
relationship between the percentage of COD and pH up to 7 (r
= 0.81, P < 0.01) (Fig. 4). Above pH 7, the infrared spectrum
showed calcium phosphate and the resultswere uninterpretable
for calcium oxalate.
Effect ofinhibitor mixtures. The results obtained with inhibi-
tor mixtures are summarized in Table I. The percentages of
COD obtained from these experiments were not different from
the sum of the effect observed with each inhibitor separately or
the sum of the calculated values. The experiments involving
human urine, added in various proportions (vol/vol) to the
synthetic solution, showed that a linear relationship existed (r =
0.98, P < 0.01) (Fig. 5) between the effect observed and the
dilution from 25% to undiluted urine. The calculation of the
contribution of pyrophosphate and citrate in the percentage of
COD obtained with each dilution is plotted as line B. From
these results, citrate and pyrophosphate together accounted for
45% of the COD obtained in undiluted urine.
Discussion
An assay was developed to measure the effect of different
substances on the formation of COD. A linear correlation was
found between the concentrations of pyrophosphate, citrate,
RNA, and heparin and the fractional content of COD. More-
over, the results showed a pH effect. The preferential formation
of COD obtained with these substances could be related to a
direct effect on COD growth. If that were the case, then these
substances would be acting as promoters of crystal growth of
COD. This explanation is unlikely because pyrophosphate,
citrate, and RNA have been shown to be inhibitors of COD
crystal growth [7].
A second explanation of the results is that the percentage of
COD observed is the result of the inhibition of the transforma-
tion of COD into COM. Tomai and Nancollas [15] have
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Fig. 2. Correlation between concentration ofpyrophosphate, citrate,
heparin, and RNA and the percentage of COD obtained. The linear
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Table 1. Effect of citrate-pyrophosphate and RNA-pyrophosphate mixtures on COD formation
%ofCOD
Observed when Observed when Calculated from
Mixture Concentration tested separately Sum tested as mixture Eqs. (3) and (4)
Citrate
Pyrophosphate
0.5 mi
1.6 x 10-2 mM
20.6 1.5
24.5 3.5
1
,
45.1 3.8 43.1 3.8 48.2
Pyrophosphate
RNA
5 x l0 mM
1.6 x l0- msi
37.1 1
14.6
1
1
51.7 4.1 46.7 7.9 51.8
5,
>,
'C
5
><0
E
U
0
% Urine
Fig. 5. Percentage of calcium oxalate dihvdrate obtained in the
inorganic solution, three mixtures of urine with inorganic solution
(25%, 50%, 75% vollvol), and undiluted urine. Line B represents the
theoretical contribution of pyrophosphate and citrate in these mixtures.
shown that COD is a less stable phase of calcium oxalate and
that COD undergoes a phase transformation into the more
thermodynamically stable COM. Moreover, these authors have
shown that this phase transformation was inhibited by some
crystal growth inhibitors.
A third hypothesis is that these substances inhibit crystal
growth of COM more than they inhibit crystal growth of COD,
thus increasing the fractional content of COD. The surface
absorption of inhibitors is higher for COM than for COD [5], a
situation that could allow the preferential absorption of crystal
growth inhibitors to COM. The two latter theories more likely
reflect what is occurring, since the substances that increase the
percentage of COD are inhibitors of calcium oxalate crystal
growth. The response that we observed could be referred to as a
phase-stabilizing effect on COD produced by inhibitors of
calcium oxalate crystal growth.
Some low-molecular-weight inhibitors such as citrate and
pyrophosphate have been found in urine, and their effects on
crystal growth have been studied extensively 116, 17]. A pH
effect on the potency of inhibitors already has been observed
for citrate [18], pyrophosphate [191, and multidentate phosphate
[201. Changes of the ionization of pyrophosphate and citrate
may be responsible for the pH effect on inhibitory activity. The
RNA-like material found in urine, as well as RNA from yeast,
has an inhibitory activity on calcium oxalate crystal growth [14,
21]. No data on the pH dependence of the effect of RNA on
calcium oxalate crystal growth could be found in the literature.
High-molecular-weight inhibitors are not yet well character-
ized in urine. Study of glycosaminoglycans extracted from urine
showed some conflicting results for inhibition of crystal growth
[22], and they seem to be much better inhibitors of crystal
aggregation [23]. However, other glycosaminoglycans like hep-
arm showed a strong effect on crystal growth [24]. It is worthy
to note that the linear correlation between inhibitor concentra-
tion and the proportion of COD obtained in our experiments
agrees with the theory of absorption of inhibitors on crystal
surface [161, Moreover, the effects induced by known inhibitors
of calcium oxalate crystal growth in our system were propor-
tionally similar to the measured effects of these same inhibitors
in a seeded crystal growth system [16]. This suggests that the
results of our assay may reflect the quantity of inhibition for
crystal growth present in solution. This system, unlike certain
other measurement systems of crystal growth, enables us to
study the effect of inhibitors at the concentrations present in
urine.
It is difficult to assess the contribution of an isolated urinary
component to the total measured inhibitory activity. A prereq-
uisite to this assessment is the additivity of the inhibition of the
different components. The additivity of inhibitors exists in
seeded growth systems for pyrophosphate, RNA, and heparin
[25].
Other experiments, including the separation and isolation of
different constituents of urine, suggest that the low-molecular-
weight inhibitors account for less than 20% of the total inhibi-
tion of the calcium oxalate crystal formation present in whole
urine [14, 23]. These estimates, based on measurements of
crystal growth in diluted urine, may be different from what
really happens in undiluted urine. Similarly, we tried to esti-
mate the contribution of the different substances tested in our
experiments on the total phase-stabilizing property of undiluted
and filtered urine. Urine induces 100% COD formation, but
only part of this effect can be explained by the substances
tested. Citrate and pyrophosphate, referred to as the low-
molecular-weight inhibitors, accounted for 45% of the COD
formation in undiluted urine. RNA-like material is present in
human urine, but its chemical structure and molecular weight
are unknown, making it impossible to determine the actual
concentration in urine at this time. Using the highest estimated
concentration of 20 mg/liter [23], RNA contributed only 16% of
the phase-stabilizing effect in our system. Nevertheless, the
RNA from yeast that was tested may not have the same
properties as the RNA-like material present in urine. Other
0 25 50 75 100
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macromolecular inhibitors of calcium oxalate crystal formation
such as acidic glycoproteins [21] also are present in urine. Low-
molecular-weight inhibitors of calcium oxalate crystal forma-
tion, including phosphocitrate [26] and citrate-metal complexes
[27], have been identified but not as yet characterized in urine.
None of these potential inhibitors was tested in this study. Also,
it is not clear whether or not, in such a complex mixture as
urine, interactions between inhibitors and some other macro-
molecular substances can occur, thus modifying the net effect
of each compound on the phase stabilization of COD.
In the system described herein, several substances (pyro-
phosphate, citrate, RNA, and heparin) have been identified that
induce a phase-stabilizing effect of COD. The effect of these
substances can be tested at concentrations likely to be found in
whole urine. Although a frozen urine poo1 was used in these
studies, the system we describe allows testing of freshly voided
urine at the voided pH and with minimal dilution. The phase-
stabilizing effect observed may reflect important factors in-
volved in calcium oxalate crystal formation in urine.
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